2021 ANNA NATIONAL SYMPOSIUM

Improvements in Itch-Related Quality of Life with Difelikefalin for Moderate-to-Severe Chronic Kidney Disease-Associated Pruritus: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies in Hemodialysis Patients

Molly Cahill, MSN, RN, ANP-C, CNN, Kansas City Kidney Consultants, Kansas City, MO
Steven Fishbane, MD, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Thomas Wooldridge, MD, Nephrology and Hypertension Associates, Ltd., Tupelo, MS
Warren Wen, PhD, Cara Therapeutics, Stamford, CT
Catherine Munera, PhD, Cara Therapeutics, Stamford, CT
Frédérique Menzaghi, PhD, Cara Therapeutics, Stamford, CT

Background: Chronic kidney disease–associated pruritus (CKD-aP) is common in patients (pts) undergoing hemodialysis (HD) with a negative impact on quality of life (QoL). Difelikefalin, a selective kappa opioid receptor agonist in development for CKD-aP, significantly reduced itch intensity based on the Worst Itching Intensity Numerical Rating Scale (WI-NRS) and was generally well tolerated in pts with moderate-to-severe CKD-aP on HD in US (KALM-1) and global (KALM-2) phase 3 studies. Here we report itch-related QoL outcomes in a pooled analysis of KALM-1 and KALM-2.

Methods: HD pts with moderate-to-severe CKD-aP were randomized to intravenous difelikefalin 0.5 mcg/kg (DFK) or placebo (PBO) 3 times/week (wk) for 12 wks. QoL was assessed with multidimensional itch-related questionnaires (5-D Itch and Skindex-10 scales) validated in this pt population. Pooled data were analyzed based on mixed model for repeated measures.

Results: There were 851 pts in the pooled studies (DFK: 426; PBO: 425). Mean (SD) baseline WI-NRS scores were 7.2 (1.4; DFK) and 7.2 (1.5; PBO), confirming moderate-to-severe itch. The primary endpoint (≥3-point WI-NRS reduction at wk 12) was met in each study; estimates for the pooled population were 51.1% with DFK vs 35.2% with PBO (P<0.001). DFK showed overall greater and clinically meaningful improvements in 5-D Itch and Skindex-10 total scores vs PBO. At wk 12, improvements in most individual 5-D Itch and Skindex-10 domains were greater with DFK vs PBO.

Conclusion: DFK administered for 12 wks to pts with moderate-to-severe CKD-aP undergoing HD resulted in significant relief of their itching accompanied by meaningful improvements in itch-related QoL.

Abstract selected for presentation at 2021 ANNA National Symposium